Reach Us +447480022765
What We Should Not Do In COPD | 46261
ISSN: 2161-105X

Journal of Pulmonary & Respiratory Medicine
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
Recommended Conferences
Share This Page

What we should not do in COPD

3rd International Conference on Chronic Obstructive Pulmonary Disease

Geertjan Wesseling

Maastricht UMC+, Netherlands

ScientificTracks Abstracts: J Pulm Respir Med

DOI: 10.4172/2161-105X.C1.010

Chronic obstructive pulmonary disease causes signifi cant morbidity and mortality worldwide. Most patients can be treated in primary care. However, even in patients with relatively mild airfl ow obstruction referral to a specialist may lead to important fi ndings, both related to the COPD and to comorbidities. Several classifi cations and grading have been proposed throughout the years that help in categorizing patients, yet not all have direct consequences for the management, that typically includes lifestyle changes of which smoking cessation and increased physical activity or even rehabilitation are paramount and pharmacotherapy. Inhaled medication is aimed at improving expiratory fl ow, reducing hyperinfl ation and infl ammation to slow down disease progression and improve quality of life and prognosis. Long acting bronchodilators have clinically signifi cant eff ects and are widely used, also in mild to moderate disease. In recent years the Asthma COPD Overlap Syndrome has been proposed, which is a misnomer and oft en an excuse to skip an adequate diagnostic process and prescribe triple-therapy in patients who would do well with only one or two diff erent drugs. Unfortunately, the majority of COPD patients are on inhaled steroids but eff ects are small, oft en not clinically relevant and side eff ects such as an increased risk of pneumonia should warrant clinicians to be more prudent in prescribing those. Self management is considered an important component of management strategies, even if eff ects on various outcomes are limited. Repeated lung function measurements are oft en performed both in primary care and in the hospital with limited if any eff ects on management. Taken together, appropriate COPD management is not only about what we should do but certainly also about what we shouldn’t.

Geertjan Wesseling has studied Biology and Medicine at the Free University of Amsterdam, Netherlands. He has completed his Training in Respiratory Medicine in 1991 and obtained his PhD in 1993. He is a Professor of Respiratory Medicine in Maastricht and coordinates the international Master in Medicine of Maastricht University, Netherlands. He is a Former President of the Dutch Pulmonology Society.

Email: [email protected]